JP Morgan Chase’s Takeda Pharmaceutical TAK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $11.9M | Buy |
744,916
+290,935
| +64% | +$4.81M | ﹤0.01% | 2654 |
|
|
2026
Q1 | $8.29M | Buy |
453,981
+211,802
| +87% | +$3.72M | ﹤0.01% | 2851 |
|
|
2025
Q4 | $3.78M | Sell |
242,179
-5,350
| -2% | -$76.5K | ﹤0.01% | 3582 |
|
|
2025
Q3 | $3.62M | Buy |
247,529
+67,770
| +38% | +$1.01M | ﹤0.01% | 3633 |
|
|
2025
Q2 | $2.78M | Sell |
179,759
-99,663
| -36% | -$1.47M | ﹤0.01% | 3664 |
|
|
2025
Q1 | $4.16M | Buy |
279,422
+195,596
| +233% | +$2.74M | ﹤0.01% | 3318 |
|
|
2024
Q4 | $1.11M | Buy |
83,826
+40,721
| +94% | +$559K | ﹤0.01% | 4559 |
|
|
2024
Q3 | $613K | Sell |
43,105
-14,599
| -25% | -$207K | ﹤0.01% | 4773 |
|
|
2024
Q2 | $747K | Sell |
57,704
-15,649
| -21% | -$207K | ﹤0.01% | 4454 |
|
|
2024
Q1 | $1.02M | Buy |
73,353
+273
| +0.4% | +$3.97K | ﹤0.01% | 4332 |
|
|
2023
Q4 | $1.04M | Sell |
73,080
-219,052
| -75% | -$3.11M | ﹤0.01% | 4306 |
|
|
2023
Q3 | $4.52M | Sell |
292,132
-15,399
| -5% | -$238K | ﹤0.01% | 2914 |
|
|
2023
Q2 | $4.83M | Buy |
307,531
+233,423
| +315% | +$3.82M | ﹤0.01% | 2892 |
|
|
2023
Q1 | $1.22M | Buy |
74,108
+57,166
| +337% | +$911K | ﹤0.01% | 3896 |
|
|
2022
Q4 | $264K | Sell |
16,942
-994
| -6% | -$13.9K | ﹤0.01% | 4896 |
|
|
2022
Q3 | $233K | Buy |
17,936
+884
| +5% | +$12.3K | ﹤0.01% | 4878 |
|
|
2022
Q2 | $239K | Sell |
17,052
-279
| -2% | -$3.98K | ﹤0.01% | 4985 |
|
|
2022
Q1 | $248K | Sell |
17,331
-94
| -0.5% | -$1.38K | ﹤0.01% | 5082 |
|
|
2021
Q4 | $237K | Sell |
17,425
-1,596
| -8% | -$22.4K | ﹤0.01% | 5259 |
|
|
2021
Q3 | $311K | Sell |
19,021
-4,487
| -19% | -$75.3K | ﹤0.01% | 5000 |
|
|
2021
Q2 | $396K | Sell |
23,508
-240,346
| -91% | -$4.09M | ﹤0.01% | 4840 |
|
|
2021
Q1 | $4.82M | Buy |
263,854
+218,193
| +478% | +$3.93M | ﹤0.01% | 3012 |
|
|
2020
Q4 | $831K | Sell |
45,661
-146,619
| -76% | -$2.57M | ﹤0.01% | 4069 |
|
|
2020
Q3 | $3.49M | Buy |
192,280
+68,358
| +55% | +$1.24M | ﹤0.01% | 2845 |
|
|
2020
Q2 | $2.22M | Sell |
123,922
-56,961
| -31% | -$1.02M | ﹤0.01% | 3038 |
|
|
2020
Q1 | $2.75M | Buy |
180,883
+126,646
| +234% | +$2.3M | ﹤0.01% | 2729 |
|
|
2019
Q4 | $1.07M | Buy |
54,237
+29,026
| +115% | +$555K | ﹤0.01% | 3805 |
|
|
2019
Q3 | $433K | Sell |
25,211
-450
| -2% | -$7.78K | ﹤0.01% | 4235 |
|
|
2019
Q2 | $450K | Buy |
25,661
+143
| +0.6% | +$2.6K | ﹤0.01% | 4289 |
|
|
2019
Q1 | $520K | Sell |
25,518
-43,660
| -63% | -$879K | ﹤0.01% | 4192 |
|
|
2018
Q4 | $1.16M | Buy |
+69,178
| New | +$1.17M | ﹤0.01% | 3646 |
|
Other funds holding TAK
BIP
JP Morgan Chase's TAK Position: Q2 2026 in Review
JP Morgan Chase increased its Takeda Pharmaceutical (TAK) stake by 64% in Q2 2026, buying an estimated $4.81M and bringing the position to 744,916 shares worth $11.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2654.
JP Morgan Chase first reported a position in TAK in Q4 2018 and has held it in 31 quarters since. 376 funds tracked by Wall St. Rank hold TAK as of Q2 2026.
- JP Morgan Chase held 744,916 shares of Takeda Pharmaceutical worth $11.9M as of Q2 2026.
- JP Morgan Chase bought 290,935 Takeda Pharmaceutical shares in Q2 2026, an estimated $4.81M.
- Takeda Pharmaceutical made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #2654 holding.
- JP Morgan Chase first reported a position in Takeda Pharmaceutical in Q4 2018 and has held it in 31 quarters since.
- 376 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.
Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.